A nurse is reviewing the use of interferon beta medications for a client diagnosed with multiple sclerosis. Which of the following statements best reflects the nurse's understanding of the appropriate use of interferon beta medications?

Multiple sclerosis (MS) is a chronic autoimmune demyelinating disorder of the central nervous system characterized by periods of relapse and remission. Disease-modifying therapies are used to reduce inflammatory activity, decrease relapse frequency, and slow long-term neurological deterioration. Interferon beta is one of the first-line treatments for relapsing forms of MS. It works by modulating the immune response to reduce autoimmune attack on myelin. Rationale: A. Interferon beta medications are indicated for acute relapses of multiple sclerosis is incorrect because these drugs are not used to treat acute exacerbations. Acute relapses are typically managed with high-dose corticosteroids to rapidly reduce inflammation. Interferon beta is a long-term disease-modifying therapy rather than an acute treatment. B. Interferon beta medication may help to reduce the frequency of relapses and slow disease progression in multiple sclerosis is correct. It modulates immune system activity, reducing inflammatory attacks on myelin and decreasing the number and severity of relapses. Over time, this can also slow the accumulation of neurological disability associated with MS progression. C. Interferon beta medications are contraindicated for clients who have multiple sclerosis is incorrect because these drugs are specifically approved for use in relapsing forms of MS. They are commonly prescribed as part of first-line disease-modifying therapy to manage the long-term course of the disease. D. Interferon beta medications are only effective in managing symptoms but do not alter the disease course of multiple sclerosis is incorrect because these medications are disease-modifying rather than purely symptomatic. They reduce disease activity by decreasing immune-mediated damage to myelin, thereby influencing the progression of MS rather than only relieving symptoms.